Background: Autoimmune diseases are chronic, debilitating conditions caused by the immune system mistakenly attacking healthy tissues. Conventional treatments mainly involve broad immunosuppression, which is associated with significant side effects, lim-ited specificity, and suboptimal long-term outcomes. Objective: This review aims to ex-plore recent advances in nanotechnology-based therapies for autoimmune diseases, fo-cusing on their mechanisms, therapeutic applications, and clinical translation potential. Methods: A comprehensive review of peer-reviewed literature was conducted to examine various nanotechnology platforms, including drug-loaded nanoparticles, antigen-specific nanomedicines, RNA interference (siRNA), CRISPR-enabled systems, and stimu-li-responsive nanocarriers. Key preclinical and clinical studies were highlighted to evalu-ate efficacy and safety. Results: Nanomedicine offers multiple advantages over traditional therapies, such as targeted drug delivery, improved bioavailability, reduced systemic tox-icity, and potential induction of immune tolerance. Notable innovations include biode-gradable polymeric nanoparticles, liposomes, micelles, exosome-mimetic nanoparticles, and magnetic nanomaterials. Emerging technologies like CRISPR-Cas9 and RNAi deliv-ered via nanoparticles are advancing immune modulation in autoimmune models. De-spite promising outcomes, several barriers remain, including toxicity concerns, scale-up manufacturing issues, and regulatory challenges. Conclusion: Nanotechnology is rede-fining autoimmune disease therapy by shifting from non-specific immunosuppression to precision-targeted approaches. Future progress lies in integrating nanomedicine with personalized medicine to tailor treatments based on individual immune profiles. Contin-ued interdisciplinary collaboration and regulatory alignment are essential to translating these innovations into clinical practice.
Barakat et al. (Fri,) studied this question.